Loading
companiesCompany
Bolt Biotherapeutics
Bolt Biotherapeutics builds antibodies that carry an immune-stimulating payload into tumours so the body's own myeloid cells attack the cancer; BDC-4182 aims this at Claudin 18.2.
Also called: Bolt BioNASDAQ:BOLT
Overview
Bolt Biotherapeutics develops Boltbody immune-stimulating antibody conjugates (ISACs), which link a tumour-targeting antibody to a Toll-like receptor agonist that activates myeloid cells inside the tumour. Its first programme, the HER2-directed trastuzumab imbotolimod (BDC-1001), was followed by BDC-3042, a Dectin-2 agonist antibody, and BDC-4182, a Claudin 18.2 ISAC that entered the clinic for gastric and pancreatic cancers.
Headquarters
Redwood City, California, US
Scorecard
All companies#435of 1244 companies, score 7
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 1 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.
Type
Biotech · NASDAQ:BOLT
Stage
Public
Website
Founded
2015
Phase 2monoclonal antibody
BDC-4182 is an experimental monoclonal antibody from Bolt Biotherapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2.
drugs
Phase 2monoclonal antibody